Key result
Two-hour point-of-care biomarker panel accurately rules out MI and 30-day events with ~99% NPV.
Why the study?
The feasibility of using a rapid biomarker panel to identify suspected ACS patients suitable for discharge within 2 hours was uncertain.
Does a 2-hour point-of-care biomarker panel (myoglobin, CK-MB, cTnI) accurately predict 12-hour troponin elevation and 30-day events in patients with suspected ACS?
Population
100 patients with suspected ACS and non-diagnostic ECG admitted to ED short stay ward
Comparison
Point-of-care myoglobin, CK-MB, and cTnI panel vs standard hospital cardiac troponin T assay
Design
Observational pilot study
Follow-up
30 days
Authors
Loading...
May aid early ACS triage; hypothesis-generating pending prospective validation before practice change.
Observational (n=100)
No
Does a 2-hour point-of-care biomarker panel (myoglobin, CK-MB, cTnI) accurately predict 12-hour troponin elevation and 30-day events in patients with suspected ACS?
A rapid 2-hour point-of-care biomarker panel shows high sensitivity and negative predictive value for ruling out ACS, potentially enabling early ED discharge.
Macdonald et al. (2008) conducted an observational in Suspected acute coronary syndrome (ACS) (n=100). Triage cardiac panel (myoglobin, CK-MB, cTnI) vs. Standard hospital cardiac troponin T assay was evaluated on 12-h cardiac troponin T elevation and 30-day events. A point-of-care biomarker panel at 2 hours predicted 12-hour cardiac troponin T elevation (sensitivity 100%, NPV 99%) and 30-day events (sensitivity 86%, NPV 97%) in suspected ACS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: